Background There is a lack of contemporary data describing patients with left ventricular (LV) systolic dysfunction post ...

Cytokinetics is committed to supporting patients with MYQORZO & You™, a personalized program for patients prescribed MYQORZO ...

MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incor ...

Cirrhotic cardiomyopathy (CCM) is a significant complication of cirrhosis, but its progression and underlying mechanisms ...

Myqorzo (aficamten) is a new therapy for oHCM, improving functional capacity and symptoms, with an annual cost of $108,400. The Myqorzo & You program provides personalized support, including insurance ...

Background A 64-year-old male was observed as an outpatient with atypical, non-exercise-induced chest pain and palpitations. He had arterial hypertension and marked concentric left ventricular ...

REUP avoids the ethical issues and costs of other procurement and recovery methods. So far, outcomes are excellent.

Background Cardiogenic shock (CS) complicating acute myocardial infarction (AMI) carries high mortality. Early ...

Supervised exercise training is safe and improves peak oxygen consumption, walking distance, and quality of life in patients with left ventricular assist devices, per a recent meta-analysis.

Ejection fraction (EF) measures the amount of blood pumped out of your heart's lower chambers, or ventricles. It's the percentage of blood that leaves your ventricle when your heart contracts. The ...

Apical hypertrophic cardiomyopathy is a rare condition where the heart walls thicken at the left ventricle’s apex, making it harder for the ventricle to pump. Symptoms are often vague or absent, but ...